SMGZY News and Press, Smiths Group Plc ADR From 01/06/22

ICU Medical Completes the Acquisition of Smiths Medical from Smiths Group plc The addition of Smiths Medical syringe and ambulatory infusion devices, vascular access, and vital care products to the ICU Medical portfolio creates a leading infusion therapy company with a more robu...

Smiths Group plc (SMGKF) Q4 2021 Earnings Conference Call September 28, 2021 3:30 AM ET Company Participants Paul Keel - Chief Executive Officer John Shipsey - Chief Financial Officer Conference Call Participants Andy Wilson - JPMorgan Will Turner - Goldman Sachs Andre Kukhnin - Credit Suisse...

The following slide deck was published by Smiths Group plc in conjunction with their 2021 Q4 earnings call. For further details see: Smiths Group plc 2021 Q4 - Results - Earnings Call Presentation

Shares of ICU Medical (NASDAQ: ICUI) , a medical device company specializing in intravenous treatment solutions, were on the move today following the announcement of a cash and stock deal for Smiths Medical. The market signaled its approval of the pending acquisition by pushing the ...

The putative sale of Smiths' medical division brings focus. The price isn't great, but it will at least tidy up the group a little. The company looks expensive for its post-sale lineup of divisions. For that reason, I am bearish. For further details see: Smiths Group: Me...

Smiths Group plc (SMGKF) Q2 2021 Results Conference Call March 26, 2021 05:00 AM ET Company Participants Andy Reynolds Smith - CEO John Shipsey - CFO Conference Call Participants Andy Wilson - JPMorgan Mark Davies Jones - Stifel Andre Kukhnin - Credit Suisse Robert Davis - Morgan Stanley Chri...

The following slide deck was published by Smiths Group plc in conjunction with their 2021 Q2 earnings call. For further details see: Smiths Group plc 2021 Q2 - Results - Earnings Call Presentation

Smiths Detection, part of Smiths Group ([[SMGZY]] +3.2%) secures an indefinite delivery-indefinite quantity contract to manufacture joint chemical agent detector adapter for US Department of Defence.The contract is worth potentially $90.8M over an ordering period of maximum 9 y...

Despite positive contributions from the company's biopharma exposure, sharp declines in short-cycle industrial, longer-cycle process, and municipal markets have hit IDEX's revenue and margins quite hard. Biopharma production, including therapeutics and vaccines, offers good long-term ...

The value of aftermarket business to the John Crane segment of Smiths Group really stood out this quarter, though weak decrementals on a modest revenue decline was a disappointment. The fate of Medical is still uncertain; after years of failed attempts to sell the business, an IPO or ...